|
CLRB | Cellectar Biosciences, Inc. |
|
|
CLRB | Cellectar Biosciences, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.26 |
| Leverage | 33.78% |
| Market Cap | $ 37.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -21.7m |
| Margin | -1679.19% |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development and commercialization of drugs for the treatment of cancer. The company is headquartered in Florham Park, New Jersey.